Enrolling By InvitationNCT07161700
SPT-300 for depression
Medication studyAges 18–66Multiple countries
Understand this study
Who could participate?
Listed age limits: 18 years to 66 years.
- Listed locations
- Chino and 41 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 2, 2025
- Recruitment status
- Enrolling By Invitation
- Enrollment listed in the registry
- 360
- Sponsor
- Seaport Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Bulgaria, Czechia, ...
- Age range
- From 18 Years to 66 Years
- Official registry ID
- NCT07161700
- Official title
Show the full official title
A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults With Major Depressive Disorder, With or Without Anxious Distress
Recruitment & locations
By invitationChino, United States · Garden Grove, United States · Glendale, United States
35 more locations
- San Jose, United States
- Cromwell, United States
- Lauderhill, United States
- Palm Bay, United States
- West Palm Beach, United States
- Atlanta, United States
- Decatur, United States
- Boston, United States
- St Louis, United States
- Brooklyn, United States
- Cedarhurst, United States
- New York, United States
- Staten Island, United States
- Independence, United States
- North Canton, United States
- Irving, United States
- Richardson, United States
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Brno, Czechia
- Prague, Czechia
- Berlin, Germany
- Schwerin, Germany
- Bad Homburg, Germany
- Chemnitz, Germany
- Budapest, Hungary
- Bialystok, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Leszno, Poland
- Poznan, Poland
- Tuszyn, Poland
- Rimavská Sobota, Slovakia
- Vranov nad Topľou, Slovakia
- Czechia
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Seaport Therapeutics.
Does this study involve medication?
Yes. The study involves medication, including SPT-300.
Who can participate?
Listed age limits: 18 years to 66 years.
Is this study still recruiting?
The registry lists this study as enrolling by invitation.
